Nadim Ahmed

Nadim Ahmed is President and Chief Executive Officer of Cullinan Therapeutics, a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, with a focus on T cell engagers, which are established in oncology and are now advancing into autoimmune diseases.

Nadim has more than 25 years of leadership experience across a range of development and commercialization roles, including Bristol Myers Squibb, where he served as President, Hematology and at Celgene Corporation where he served as President, Global Hematology & Oncology. At Bristol Myers Squibb and Celgene, Nadim oversaw multiple product launches and served as a member of both companies’ Leadership Teams.

Nadim has expertise in various treatment modalities, including small molecules, biologics, and cell therapy. Nadim currently serves on the board of directors of Disc Medicine, a publicly held company.